SynthesisFrontiers in immunology2026
NK cell adoptive transfer in acute myeloid leukemia: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-related changes of FCGR3AEBioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) remains associated with high relapse rates and poor long-term survival, particularly in refractory patients or those ineligible for hematopoietic stem cell transplantation (HSCT). Adoptive transfer of natural killer (NK) cells has emerged as a promising immunotherapeutic strategy due to intrinsic cytotoxicity, low risk of graft-versus-host disease (GVHD), immune restoration capacity, and feasibility of allogeneic off-the-shelf manufacturing. Methods: A systematic review of phase 1-2 clinical trials evaluating non-genetically modified NK-cell adoptive transfer was performed using PubMed and EMBASE (2000-2024). Study selection and data extraction were conducted independently by two reviewers in Rayyan Results: Of 790 records identified, 29 studies were included, predominantly single-arm phase I/II trials (one randomized phase II). In R/R AML (11 studies; 217 patients), pooled response rate was 35% (95% CI 29-42; I²=30%), with 20.2% proceeding to HSCT. Higher responses were observed in strategies enhancing NK activation or persistence, including expanded multi-infusion platforms and CIML-NK. In low-/intermediate-risk AML in remission (3 studies; 38 patients), pooled 1-year DFS was 82% (95% CI 56-100; I²=0). In high-risk AML in remission and ineligible for HSCT (5 studies; 59 patients), pooled 1-year DFS was 26% (95% CI 12-55; I²=84). In studies combining NK transfer with haploidentical HSCT (9 studies; 303 patients), pooled 1-year DFS was 40% (95% CI 27-57; I²=94). Toxicities were generally mild, GVHD rates were low (0-8%), and severe events were uncommon. NK-cell persistence was typically short, improving with multiple infusions and CIML approaches. Conclusion: Adoptive allogeneic NK-cell transfer appears safe and clinically promising, particularly for patients unfit for intensive therapy or HSCT. At present, its use should remain limited to clinical trials. Future studies should define the optimal approach that maximizes clinical activity while maintaining low toxicity and achieving durable persistence of allogeneic NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.